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Abstract: The joint consensus panel of the European Ath-
erosclerosis Society (EAS) and the European Federation 
of Clinical Chemistry and Laboratory Medicine (EFLM) 
recently addressed present and future challenges in the 
laboratory diagnostics of atherogenic lipoproteins. Total 
cholesterol (TC), triglycerides (TG), high-density lipo-
protein cholesterol (HDLC), LDL cholesterol (LDLC), and 
calculated non-HDLC (=total – HDLC) constitute the pri-
mary lipid panel for estimating risk of atherosclerotic 
cardiovascular disease (ASCVD) and can be measured in 
the nonfasting state. LDLC is the primary target of lipid-
lowering therapies. For on-treatment follow-up, LDLC 
shall be measured or calculated by the same method to 
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attenuate errors in treatment decisions due to marked 
between-method variations. Lipoprotein(a) [Lp(a)]-
cholesterol is part of measured or calculated LDLC and 
should be estimated at least once in all patients at risk of 
ASCVD, especially in those whose LDLC declines poorly 
upon statin treatment. Residual risk of ASCVD even under 
optimal LDL-lowering treatment should be also assessed 
by non-HDLC or apolipoprotein B (apoB), especially in 
patients with mild-to-moderate hypertriglyceridemia 
(2–10 mmol/L). Non-HDLC includes the assessment of rem-
nant lipoprotein cholesterol and shall be reported in all 
standard lipid panels. Additional apoB measurement can 
detect elevated LDL particle (LDLP) numbers often uni-
dentified on the basis of LDLC alone. Reference intervals 
of lipids, lipoproteins, and apolipoproteins are reported 
for European men and women aged 20–100 years. How-
ever, laboratories shall flag abnormal lipid values with 
reference to therapeutic decision thresholds.
Keywords: apolipoprotein B; atherosclerotic cardiovascu-
lar disease; LDL cholesterol; lipoprotein(a); non-HDL cho-
lesterol; remnant cholesterol.
Introduction
In the new era of very low LDL-cholesterol (LDLC) concen-
trations, achievable with more intensive and novel lipid-
lowering therapies, increasing attention is being focused 
on the assessment of lipid-related residual risk of athero-
sclerotic cardiovascular disease (ASCVD) using additional 
biomarkers beyond LDLC [1].
An important prerequisite to address present and 
future challenges of ASCVD prevention is the harmoniza-
tion of serum lipid and lipoprotein profiles produced by 
established and emerging laboratory tests and techniques. 
To that end, the multidisciplinary consensus panel of the 
European Atherosclerosis Society (EAS) and the European 
Federation of Clinical Chemistry and Laboratory Medi-
cine (EFLM) recently published recommendations on the 
quantification of atherogenic lipoproteins in nonfasting 
and fasting blood samples [1, 2]. This article summarizes 
the consensus-based recommendations of this expert 
panel which aimed to provide appropriate guidance on 
the pre-analytical, analytical, and post-analytical phases 
of laboratory testing of atherogenic lipoproteins.
The key recommendations are given in Table 1. Based 
on the Copenhagen General Population Study [3], refer-
ence nonfasting concentrations for lipids and (apo)lipo-
proteins are reported for 54,129 European women and 
42,126 European men aged 20–100 years and not on lipid-
lowering therapy in Tables 2 and 3.
I.  Which atherogenic lipoproteins 
should be measured?
LDL particles
Assessment of LDLC is a key component of the manage-
ment of risk of ASCVD [4–6]. Circulating LDL particles 
(LDLPs) are highly atherogenic and there is a direct, 
graded relationship between LDLC concentration and the 
incidence of ASCVD observed in randomized controlled 
trials, prospective epidemiological cohort studies, and 
Mendelian randomization studies [7, 8].
Despite the overwhelming evidence that LDLC-tar-
geted therapies effectively reduce ASCVD in the popula-
tion, many individuals experience ASCVD-related events 
or progression of atherosclerosis despite not having ele-
vated LDLC or even concentrations <1.8 mmol/L [9]. This 
residual risk indicates that a focus solely on the measure-
ment of LDLC is not an optimal strategy for all patients, in 
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part explained by accumulating evidence that the number 
of LDLPs measured by lipoprotein subfractionation tech-
niques is more strongly causally related to ASCVD than 
the cholesterol content of the particles [9, 10].
All LDLPs are atherogenic, but their concentration 
is not always reflected by LDLC measurement because 
the cholesterol content in the particles can vary widely 
between individuals according to the continuous remod-
eling of lipoproteins in blood [10]. Small lipid-depleted 
LDL subfractions contain less cholesterol than larger 
ones. They are typically predominant in patients with 
moderately elevated triglyceride (TG) concentrations or 
related conditions, such as diabetes and the metabolic 
syndrome, without necessarily having high LDLC con-
centration [11]. These compacted LDLPs are the products 
of exchange of cholesteryl esters with TG from larger, 
TG-rich very-low-density lipoprotein (VLDL) particles 
(Figure 1). Concomitantly, smaller high-density lipopro-
tein (HDL) particles are also formed in this pathway, as 
typically manifested in the atherogenic dyslipidemic triad 
involving hypertriglyceridemia, increased small dense 
LDLP, and low HDL cholesterol (HDLC) concentration [11].
While earlier studies emphasized the atherogenicity 
of small LDLPs, it is now recognized that all LDLPs are ath-
erogenic, regardless of size [10]. Thus, the primary focus 
of treatment should remain the reduction of the number 
(concentration) of LDLPs, without efforts to distinguish 
between large and small LDL subfractions [1]. Measure-
ment of apolipoprotein B (apoB), the major protein com-
ponent of LDL, or advanced measurement of LDLP (not yet 
widely available) can also be used to assess the number of 
LDLPs [10, 12].
The total cholesterol (TC) to HDLC ratio has been 
proposed as a surrogate marker of the number of LDLPs 
– associated with low HDLC and hence higher TC/HDLC 
ratio in individuals with atherogenic dyslipidemia [10]. 
The TC/HDLC ratio may be considered as an alternative to 
LDLP for risk estimation, but not for diagnosis or as thera-
peutic decision limit because a low ratio due to high HDLC 
can be misleading: this may lead to assuming a low risk 
Table 1: Key EAS/EFLM recommendations for testing of atherogenic lipoproteins [1, 2].
Pre-preanalytical phase (test ordering)
  Comprehensive testing of atherogenic lipoproteins should include tests to assess the risk conferred by LDL particles, remnant particles, 
and, in selected cases, Lp(a).
Preanalytical phase (test sampling)
  Fasting is not routinely required for assessing the lipid profile.
  Consider fasting sample when nonfasting TG are ≥4.5 mmol/L (400 mg/dL); however, this is not a requirement.
  Take 2–3 serial blood specimens, at least 1 week apart, to allow to average for biological variation (importantly when test results are near 
the treatment decision thresholds).a
Analytical phase (test measurement)
  Follow-up of measured or calculated LDLC and non-HDLC of a patient, from baseline to on-treatment measurements, should be ideally 
performed with the same method (and preferably the same laboratory).b
  Clinicians should be notified when the laboratory test changes from a method to another.
  The Martin-Hopkins equation may be preferable for calculation of LDLC in patients with low LDLC concentration <1.8 mmol/L (70 mg/dL) 
and/or TG concentration 2.0–4.5 mmol/L (175–400 mg/dL), and in nonfasting samples.
  Direct LDLC assays should be used for calculation of RemnantC and for assessment of LDLC when TG concentration is ≥4.5 mmol/L 
(400 mg/dL).
  Lp(a)-corrected LDLC should be assessed at least once in patients with suspected or known high Lp(a), or if the patient shows a poor 
response to LDL-lowering therapy.
  ApoB assays currently provide the most accurate measurement of overall burden of atherogenic particles in the fasting and nonfasting state.
Postanalytical phase (test reporting)
  Laboratories should automatically calculate and report non-HDLC on all lipid profiles; RemnantC could also be reported.
  Laboratory reports should flag abnormal concentrations based on decision thresholds.
  Extremely high concentrations beyond the reference limits should alert clinicians (interpretative commenting on test report).
Post-postanalytical phase (test interpretation and use)
  LDLC is the primary target of lipid-lowering therapy.
  When LDLC goal is achieved, non-HDLC or apoB should be preferred as secondary treatment targets in patients with TG 2–10 mmol/L 
(175–880 mg/dL), diabetes, obesity or metabolic syndrome.
aAvoid measurements within ~2 months after acute myocardial infarction, acute trauma, surgery, acute infection or inflammatory illness, 
or pregnancy. Patients should maintain their usual diet in the preceding 2 weeks, and avoid strenuous exercise. bRemove serum from cells 
(centrifugation) within 3 h of blood sampling, and perform lipid measurements within 1–2 days of collection. However, before measurement 
specimens can safely be stored at 4 °C for 3 days, at –20 °C for 1 month, and at −80 °C for 1–2 years.
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even if the patient has high LDLC. The components of the 
ratio, TC and HDLC, have to be managed separately.
Remnant particles
Postprandial accumulation of TG-rich remnant particles 
in blood is an important factor in atherogenesis [13, 14]. 
These lipoproteins contain a higher load of cholesterol 
that is not accounted for in typical fasting lipid profiles. 
Nonfasting lipid profiles, therefore, can potentially be 
more relevant to the estimation of an individual’s cardi-
ovascular risk than fasting lipids as in real life the post-
prandial state predominates most of our 24-h cycle [15, 16].
TG-rich chylomicrons secreted from the intestine, 
and VLDL secreted from the liver, are rapidly depleted 
Table 2: Concentration distribution of nonfasting lipids, lipoproteins, and apolipoproteins in 54,129 women in the Copenhagen General 














mmol/L   mg/dL mmol/L   mg/dL mmol/L   mg/dL mmol/L   mg/dL mmol/L   mg/dL
Triglycerides
 20–39   0.45   40   0.73   65   0.98   87   1.4   121   2.8   248
 40–65   0.50   44   0.84   74   1.2   103   1.7   148   3.6   317
 66–100   0.59   52   0.98   87   1.4   120   1.9   170   3.8   340
Total cholesterol
 20–39   3.3   127   4.2   162   4.7   182   5.3   205   6.9   267
 40–65   3.8   147   5.0   193   5.6   217   6.3   244   7.9   306
 66–100   4.3   166   5.5   213   6.1   236   6.8   263   8.2   317
LDL cholesterol
 20–39   1.4   54   2.1   81   2.6   101   3.1   120   4.4   170
 40–65   1.7   66   2.6   101   3.2   124   3.8   147   5.3   205
 66–100   1.9   73   3.0   116   3.5   135   4.1   159   5.5   213
Remnant cholesterol
 20–39   0.19   7.4   0.33   13   0.45   17   0.62   24   1.2   48
 40–65   0.21   8.1   0.38   15   0.53   20   0.76   29   1.5   60
 66–100   0.26   10   0.45   17   0.61   24   0.86   33   1.6   62
Non-HDL cholesterol
 20–39   1.7   67   2.6   99   3.1   118   3.7   142   5.3   203
 40–65   2.1   82   3.1   121   3.8   147   4.6   176   6.3   242
 66–100   2.4   93   3.5   137   4.2   162   4.9   190   6.5   251
HDL cholesterol
 20–39   0.91   35   1.3   51   1.6   61   1.9   73   2.5   98
 40–65   0.93   36   1.4   55   1.7   67   2.1   80   2.8   108
 66–100   0.98   38   1.5   58   1.9   72   2.2   86   3.0   117
Lipoprotein(a)   nmol/L   mg/dL   nmol/L   mg/dL   nmol/L   mg/dL   nmol/L   mg/dL   nmol/L   mg/dL
 20–39   1.1   1.4   5.4   4.3   15   8.5   43   22   207   97
 40–65   1.6   1.5   6.8   4.9   17   9.8   60   30   242   113
 66–100   1.9   1.6   7.4   5.2   19   10   64   31   250   116
Apolipoprotein B   g/L   mg/dL   g/L   mg/dL   g/L   mg/dL   g/L   mg/dL   g/L   mg/dL
 20–39   0.51   51   0.69   69   0.82   82   0.98   98   1.47   147
 40–65   0.59   59   0.83   83   1.00   100   1.21   121   1.79   179
 66–100   0.67   67   0.94   94   1.11   111   1.31   131   1.87   187
Nonfasting triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDLC), and apolipoprotein B concentrations were 
measured by automated assays (Thermo Scientific Konelab, Vantaa, Finland). Low-density lipoprotein cholesterol (LDLC) was calculated by 
the Friedewald equation when TG were <4 mmol/L and was measured directly (Konelab) when TG were ≥4 mmol/L. Non-HDL cholesterol was 
calculated as TC minus HDLC. Remnant cholesterol was calculated as TC minus LDLC minus HDLC. The first 5592 individuals included in the 
Copenhagen General Population Study had lipoprotein(a) total mass measured using a sensitive immunoturbidimetric assay from DiaSys 
(DiaSys Diagnostic Systems, Holzheim, Germany), while all remaining individuals in the study had lipoprotein(a) measurements done using 
the apolipoprotein(a) isoform insensitive Denka Seiken assay (Denka Seiken, Tokyo, Japan) or the Roche second generation lipoprotein(a) 
assay developed by Denka Seiken (Roche Diagnostics, Rotkreuz, Switzerland) [3].
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of part of their TG content and acquire cholesteryl esters 
from HDL in the circulation (Figure 1). These cholesterol-
enriched remnant particles may enter the arterial intima 
and contribute to atherosclerosis, whereas nascent chy-
lomicrons and very large VLDL particles do not cross the 
endothelial layer [17]. Mendelian randomization studies 
suggest that life-long high serum concentrations of 
TG-rich lipoproteins or their remnants are causally asso-
ciated with increased risk of ASCVD and all-cause mortal-
ity [17, 18].
Direct “homogeneous” assays have been developed 
to specifically measure cholesterol in remnant parti-
cles (RemnantC) and some have revealed significant 
associations of RemnantC with ASCVD [19, 20]. An alter-
native is to calculate RemnantC as TC – HDLC – LDLC, 
because RemnantC corresponds to all cholesterol not 
found in LDL and HDL, that is, in all VLDL and inter-
mediate-density lipoproteins (IDL). In the nonfasting 
state a relatively small amount of cholesterol can also 
be found in chylomicron remnants. Because both newly 
secreted chylomicrons and VLDL rapidly undergo lipol-
ysis, any residual circulating chylomicrons and VLDL 
can be considered remnants [17]. Direct LDLC (dLDLC) 
measurement should preferably be used in the calcula-
tion of RemnantC;  otherwise RemnantC simply equals 
TG/2.2 (in mmol/L) when Friedewald-calculated LDLC is 
Table 3: Concentration distribution of nonfasting lipids, lipoproteins, and apolipoproteins in 42,126 men in the Copenhagen General 














mmol/L   mg/dL mmol/L   mg/dL mmol/L   mg/dL mmol/L   mg/dL mmol/L   mg/dL
Triglycerides
 20–39   0.54   48   0.96   85   1.4   128   2.2   190   5.1   454
 40–65   0.61   54   1.10   100   1.7   146   2.5   219   5.5   485
 66–100   0.62   55   1.10   98   1.6   140   2.3   201   4.6   404
Total cholesterol
 20–39   3.3   128   4.3   166   4.9   189   5.6   217   7.2   278
 40–65   3.9   151   5.0   193   5.6   217   6.3   244   7.9   305
 66–100   3.8   147   5.0   193   5.6   217   6.3   244   7.6   294
LDL cholesterol
 20–39   1.5   58   2.4   93   2.9   112   3.5   135   5.0   193
 40–65   1.8   70   2.8   108   3.4   131   4.0   155   5.4   209
 66–100   1.8   70   2.7   104   3.3   128   3.9   151   5.0   193
Remnant cholesterol
 20–39   0.22   8.5   0.43   17   0.64   25   0.95   37   1.8   71
 40–65   0.26   10   0.51   20   0.74   29   1.1   43   2.0   76
 66–100   0.27   10   0.50   19   0.71   27   1.0   39   1.7   67
Non-HDL cholesterol
 20–39   2.0   76   3.0   115   3.6   140   4.4   170   6.2   238
 40–65   2.4   92   3.6   137   4.3   164   5.5   213   6.6   255
 66–100   2.3   89   3.4   133   4.1   158   4.8   184   6.1   237
HDL cholesterol
 20–39   0.67   26   1.0   39   1.2   85   1.5   56   2.0   76
 40–65   0.72   28   1.1   42   1.3   52   1.7   64   2.4   93
 66–100   0.76   29   1.2   46   1.5   56   1.8   70   2.6   101
Lipoprotein(a)   nmol/L   mg/dL   nmol/L   mg/dL   nmol/L   mg/dL   nmol/L   mg/dL   nmol/L   mg/dL
 20–39   1.0   1.2   5.5   4.3   14   8.3   49   24   219   102
 40–65   1.1   1.4   5.8   4.4   15   8.9   51   25   226   105
 66–100   1.1   1.4   6.2   4.6   17   9.5   50   25   211   99
Apolipoprotein B   g/L   mg/dL   g/L   mg/dL   g/L   mg/dL   g/L   mg/dL   g/L   mg/dL
 20–39   0.56   56   0.81   81   0.99   99   1.22   122   1.86   186
 40–65   0.67   67   0.96   96   1.16   116   1.41   141   2.04   204
 66–100   0.66   66   0.93   93   1.11   111   1.32   132   1.86   186
Laboratory measurements and calculations were performed as described in the footnote of Table 2 [3].
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used, i.e. TC – HDLC – (TC – HDLC – TG/2.2), and it does 
not add clinical information beyond TG concentration 
[1]; however, it focuses the attention on the cholesterol 
content of remnants rather than the TG content.
RemnantC also contributes to non-HDLC which is 
calculated as TC – HDLC [1]. This term is independent of 
the Friedewald term and therefore not correlated as tight 
with TG concentrations as calculated RemnantC, and thus 
represents an additional clinically valuable marker. Rem-
nantC, measured or calculated, differs from non-HDLC in 
that non-HDLC contains RemnantC plus LDLC and does 
not differentiate between these two causal risk factors [1]. 
Non-HDLC also includes the cholesterol of lipoprotein(a) 
[Lp(a)].
Lipoprotein(a) particles
Lp(a) is an LDL-like particle with one molecule of 
apoB to which an additional apolipoprotein, apo(a), is 
attached. This apolipoprotein shows considerable size 
polymorphism originating from a variable number of 
kringle IV type 2 (KIV-2) repeats of apo(a) [21, 22]. This 
size polymorphism is the most important determinant 
of the hepatic production rate of Lp(a): serum Lp(a) con-
centrations and number of KIV-2 repeats are inversely 
correlated, which results in marked genetic variation of 
Lp(a) concentrations [21, 22]. Elevated baseline and on-
statin treatment Lp(a) concentration above the 80th per-
centile of the general population (50 mg/dL) is a strong 
genetic risk factor for cardiovascular disease independ-
ent of LDLC [23, 24]. This is recognized by the codes of 
International Classification of Diseases for elevated 
Lp(a) and family history of elevated Lp(a), introduced 
in response to the US National Heart, Lung, and Blood 
Institute recommendation [25]. High Lp(a) concentra-
tion through a correspondingly low number of KIV-2 
repeats are also associated with a higher risk of mortal-
ity in the general population [3].
One of the major differences between Lp(a) and 
LDLPs is that LDLs are effectively lowered by statins, 
whereas Lp(a) is typically resistant to this treatment [24]. 
In statin-treated patients the Lp(a)-associated risk for 
ASCVD becomes an even better predictor for residual risk 
as soon as the LDL-associated risk is decreased by statin 
therapy [24]. Although proprotein convertase subtilisin/
kexin type 9 (PCSK9) inhibitors and other novel therapies 
reduce Lp(a) and may contribute to reduction in ASCVD 
[26, 27], it is yet unknown whether Lp(a) lowering per se 
contributes to the clinical benefit of these novel therapies 
[25]. Although recent studies with PCSK9 inhibitors were 
not designed to target patients with high Lp(a) concen-
trations, they nevertheless revealed that patients with 
higher baseline Lp(a) concentration experienced greater 
absolute reductions in Lp(a) and tended to derive greater 
clinical benefit from PCSK9 inhibition [27, 28]. Drugs on 
the horizon that specifically target Lp(a) with an Lp(a)-
lowering potential of 80% and more will have to prove 
the benefit of an isolated lowering of Lp(a) on ASCVD out-
comes [29].
Recommendation – I
 – Comprehensive testing of atherogenic lipopro-
teins should use a biomarker, or a panel of multiple 
markers, to assess the risk of ASCVD associated not 
only with LDLPs, but also remnant particles and, in 
selected cases, Lp(a) particles.
 – Recommendations for selection of atherogenic lipo-
protein tests in different clinical settings are summa-
rized in Table 4.
Figure 1: Intravascular remodeling of lipoproteins contributing to 
the typical serum lipid profile of atherogenic dyslipidemia.
TG-rich chylomicrons (CM) secreted from the intestine, and VLDL 
secreted from the liver, are remodeled in the circulation primarily 
through the actions of lipoprotein lipase (LPL), hepatic lipase (HL), 
and cholesteryl ester transfer protein (CETP). The hydrolysis of 
TG by LPL, leading to liberation of free fatty acids (FFA), and the 
acquisition of cholesteryl esters (CE) from HDL by CETP generates 
smaller, cholesterol-enriched remnant particles which are depleted 
of part of their TG content and contributes to increased RemnantC 
concentrations measured in serum. Higher VLDL output resulting 
from FFA flux to the liver activates CETP, which results in TG 
enrichment of HDL and LDL through increased exchange and transfer 
of TG and cholesteryl ester. These cholesterol-depleted, TG-enriched 
LDL and HDL particles are also modified by HL, producing smaller 
LDL and HDL and contributing to lower serum concentrations of 
LDLC and HDLC, respectively, as typically manifested in the serum 
lipid profile of a patient with atherogenic dyslipidemia – frequently 
accompanying insulin resistance and metabolic syndrome with 
increased FFA flux to the liver.
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II.  What is the standard lipid 
profile?
The traditional lipid profile of TC, TG, HDLC, and LDLC 
remains the primary approach for diagnosis and ASCVD 
risk classification [30]. A cost-efficient approach is to 
employ measurements of three markers (TC, TG, HDLC) 
and from these calculate LDLC and non-HDLC. RemnantC 
can also be calculated if directly measured LDLC is used 
in the equation.
ApoB measurement is not usually part of the stand-
ard lipid profile and ASCVD risk estimation models. 
Monogenic disorders such as familial hypercholester-
olemia (FH) can be easily recognized from the standard 
lipid panel without the need to measure apoB [31, 32]. 
In patients with mild-to-moderate hypertriglyceridemia, 
defined as 2–10  mmol/L [33], elevated baseline and on-
treatment apoB helps identify the atherogenic dyslipi-
demia related to remnant lipoproteins combined with 
small dense LDLPs that is not reflected by LDLC and 
non-HDLC.
Lp(a) measurement should be considered at least 
once in each adult person’s lifetime to identify those 
with high inherited Lp(a) concentrations, in particular 
among patients with premature ASCVD, with FH, with 
a family history of premature ASCVD and/or elevated 
Lp(a), or with recurrent ASCVD despite statin treatment 
[22]; Lp(a) measurement may also be considered in those 
with aortic valve stenosis. However, Lp(a) measurement 
should not be included in repeated lipid profile meas-
urements within the same patient, as Lp(a) concentra-
tions exhibit little variation over a lifetime. Exceptions 
from this rule are transition to menopause, pregnancy, 
oral contraceptive use, renal impairment, or when spe-
cific Lp(a)-lowering treatment is administered [21]. Lp(a) 
concentrations do not change in response to normal food 
intake and are minimally increased in inflammation, 
although the influence of acute illness or acute phase 
reactions on Lp(a) concentration is discussed controver-
sially [34].
Recommendation – II
 – The ‘standard lipid profile’ used for cardiovascular 
risk prediction includes TC, TG, HDLC, LDLC, non-
HDLC, and optionally – if directly measured LDLC is 
used – calculated RemnantC. A ‘minimal lipid profile’ 
including only TC and TG can be considered in coun-
tries where costs are a major issue such as developing 
countries [35].
 – An ‘expanded lipid profile’ including Lp(a) or 
apoB should be used in selected cases (Table 4) 
[35]. ‘Advanced lipid profiles’ such as lipopro-
tein subclasses and apolipoprotein profiles have 
been  introduced in some laboratories but their 
added value in a clinical setting still needs to be 
validated [1].
Table 4: Recommendations for the clinical indications for lipid and 
(apo)lipoprotein quantitation [1, 4].









 TCa   YESa   Optionalb   Optionalb   Optionalb
 HDLCc   YESd   YES   NO   NO
 TG   YES   YES   YES   NO
 LDLC   YES   YES   YES   YES
 RemnantCa   Optionale   Optionale   NO   Optionale
 Non-HDLCa   YES   NOf   NO   YESg
Additional tests
 ApoBh   YESg   YESg   NO   Optionalg
 Lp(a)   YESi   YESi   Not yetj   Not yetj
aIn nonfasting samples this will also include cholesterol in 
chylomicrons and their remnants; however, in the majority of 
individuals chylomicrons are rapidly converted into remnants 
(within 5–10 min) after delivery from lymphs to the blood stream. 
bTo be considered in a minimal lipid profile (TC and TG only) or when 
LDLC is not available. cOr ApoA-I if available. dIn combination with 
TC, if HDLC is entered as a separate variable in the risk estimation 
model. Ratios of TC/HDLC, non-HDLC/HDLC, or apoB/apoA-I which 
reflect the balance between atherogenic and neutral lipoproteins 
can be considered as an alternative for risk estimation, but not 
for diagnosis or as treatment targets. The components of the 
ratio have to be managed separately. eRemnantC, calculated as 
TC – HDLC – LDLC, is all cholesterol found in TG-rich lipoproteins 
VLDL, IDL, and, in the nonfasting state, additionally chylomicron 
remnants. RemnantC is included in non-HDLC, but non-HDLC does 
not differentiate between LDLC and RemnantC. RemnantC is the 
part of non-HDLC in addition to LDLC that needs reduction in some 
patients. Directly measured LDLC should preferably be used in 
the calculation of RemnantC, or RemnantC could be measured 
directly. fNon-HDLC, calculated as TC – HDLC, is all cholesterol in 
atherogenic lipoproteins: LDL, remnants, and Lp(a). None of the 
hyperlipidemias can be characterized by non-HDLC because the 
composite marker does not differentiate between the atherogenic 
lipoprotein-cholesterol fractions. gIn patients with mild-to-moderate 
hypertriglyceridemia, 2–10 mmol/L (175–880 mg/dL), diabetes, 
obesity or metabolic syndrome. hOr advanced LDLP measurement if 
available. iAt least once in each adult person’s lifetime, especially in 
patients with premature ASCVD (men <55 years, women <60 years), 
family history of premature ASCVD and/or elevated Lp(a), FH, 
recurrent ASCVD despite optimal lipid-lowering treatment. jUnless 
approved treatment is available to substantially reduce Lp(a) 
concentration and Lp(a)-related risk.
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III.  When to use fasting and 
nonfasting blood samples?
Fasting blood samples have previously been the stand-
ard for measuring TG, because the fasting state reduces 
variability of TG concentrations and allows for a slightly 
more standardized LDLC estimation with the Friedewald 
equation; however, a fasting sample does not capture the 
average atherogenic lipid profile seen in the patient over 
a 24-h period [16]. In consequence, extended (8–12  h) 
fasting is no longer routinely required for the deter-
mination of a lipid profile [2]. Findings from popula-
tion studies showed that despite minor postprandial 
increases in TG and RemnantC, quantitative changes in 
other lipids, lipoproteins, and apolipoproteins appear 
to be negligible in response to the habitual meal intake 
for most individuals [2]. For patients, laboratories, and 
clinicians alike, nonfasting lipid profiles represent an 
operational simplification without significant negative 
implications for prognostic, diagnostic, and therapeu-
tic options for ASCVD prevention [36]. Regardless, it 
may remain prudent to counsel the patients to avoid an 
extremely high-fat or fast-food meal (e.g. a burger, fries) 
in the preceding 12 h [37].
Nonfasting lipid profiles are now endorsed by several 
guidelines including those in Europe, the UK, Canada, 
Brazil, and the US [4–6, 35, 38]. Nonfasting and fasting 
measurements of the lipid profiles must be viewed as 
complementary and not mutually exclusive. Fasting is 
certainly not critical for first-time screening and general 
risk estimation, or to diagnose an isolated hypercholes-
terolemia such as FH or elevated Lp(a) without concomi-
tant high TG [2]. Fasting is an option when nonfasting 
TG are ≥4.5 mmol/L, a concentration seen in ~3–5% of 
nonfasting individuals in the general population (Tables 
2 and 3) [17], and for the phenotypic diagnosis or ther-
apeutic follow-up of mixed dyslipidemia or isolated 
hypertriglyceridemia; however, this is not a require-
ment and a random nonfasting blood sample will still 
best capture the average TG concentration in a given 
patient. Fasting may also be recommended for start-
ing medications that cause severe hypertriglyceridemia 
(e.g. isotretinoin) in genetically predisposed individu-
als, for patients recovering from hypertriglyceridemic 
pancreatitis, and when additional laboratory tests that 
require fasting or morning samples (e.g. fasting glucose, 
or markers with circadian rhythm) are requested [2]. 
The EFLM Preanalytical Phase Working Group recently 
produced guidance on how to standardize fasting blood 
sampling if needed [37, 39].
Recommendation – III
 – Fasting is not routinely required for the determination 
of a lipid profile.
 – In patients in whom an initial nonfasting lipid pro-
file reveals a TG concentration ≥4.5 mmol/L, a repeat 
lipid profile in the fasting state could be performed to 
assess fasting TG concentration; however, this is not 
a requirement.
IV.  Are LDLC measurements or 
calculations reliable?
Operational definition of LDL
Beta-quantification, the US Centers of Disease Control 
(CDC) Reference Method for LDLC, combines ultracen-
trifugation to remove VLDL and chylomicrons and hepa-
rin-Mn2+ precipitation to separate LDLPs, including Lp(a), 
from HDL [40]. With beta-quantification, the lipopro-
tein fraction in the density range of 1.006–1.063 g/mL is 
defined as LDL, and the fraction in the density range of 
1.063–1.21 g/mL is defined as HDL [40]. However, it is not 
widely recognized that the LDLC fraction on beta-quantifi-
cation also contains the cholesterol from IDL with density 
1.006–1.019 g/mL and Lp(a) with density 1.04–1.13 g/mL. 
LDLC assays that attempt to specifically measure choles-
terol in LDL may, therefore, show discordant results com-
pared to the reference method [41].
Direct LDLC and HDLC assays
The “homogeneous” or “direct” LDLC (dLDLC) and HDLC 
(dHDLC) assays have largely replaced the older ultracen-
trifugation and precipitation techniques, particularly 
for HDLC, but these measurements cannot be generally 
assumed to provide the same clinical information [40, 
41]. The total error of measurement combines systematic 
bias (deviation from “true” value) and random impreci-
sion. Despite improved analytical precision due to auto-
mation, data indicate that results can vary significantly 
between dLDLC and dHDLC assays from different manu-
facturers [41]. Most discrepancies – with marked biases 
between assays and the CDC Reference Methods – are 
observed in samples from patients with hypertriglyceri-
demia >2  mmol/L, mixed dyslipidemia, or other con-
ditions involving altered lipoprotein composition and 
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remodeling, such as diabetes and chronic kidney disease 
[41]. Direct measurements of dLDLC and dHDLC in nor-
molipidemic samples usually meet the National Choles-
terol Education Program (NCEP) total error goals of ≤12% 
and ≤13%, respectively, but total error ranged from −26% 
to +32% for dLDLC and −20% to +36% for dHDLC in a 
comprehensive study of different assays in dyslipidemic 
samples [42]. Most discordances in dyslipidemic samples 
are observed at lower concentration ranges of LDLC 
(<1.8 mmol/L) and HDLC (<1.0 mmol/L) [42]. These errors 
result in misclassifications with respect to ASCVD risk 
assessment depending on the type of assay, as observed 
in accuracy-based external quality assessment surveys of 
hypertriglyceridemic samples organized across different 
laboratories [43]. The biases noted in dHDLC measure-
ments affect the calculations of LDLC and non-HDLC, as 
HDLC is used in the calculations [43].
The biases noted in dLDLC and dHDLC assays when 
analyzing dyslipidemic samples suggest that non-specific 
cross-reaction takes place, reflecting difficulties in selec-
tively measuring the cholesterol in LDL or HDL fractions 
when atypical lipoproteins are present. The different 
manufacturers’ direct methods do not measure the same 
LDL and HDL subfractions [40, 41]. This non-selectivity 
error is of major concern in the contemporary treatment 
era in which very low LDLC concentrations <1.8 mmol/L 
are increasingly seen with highly efficacious LDL-lower-
ing therapies, and in which hypertriglyceridemic samples 
–TG > 2 mmol/L seen in ~25% of individuals in the general 
population (Tables 2 and 3) [17] – cause a greater analyti-
cal problem due to the increasing prevalence of obesity, 
metabolic syndrome, and diabetes mellitus [11].
Calculated LDLC
LDLC calculated with the Friedewald formula, cLDLC = TC 
– HDLC – VLDL cholesterol (VLDLC), has its limitations. 
The equation uses a fixed TG:cholesterol ratio (TG/2.2 in 
mmol/L or TG/5 in mg/dL) to estimate VLDLC and assumes 
lack of chylomicrons which are more TG-rich than VLDL 
[44]. Because the TG:cholesterol ratio in TG-rich lipo-
proteins progressively increases as hypertriglyceridemia 
becomes more severe, the equation overestimates VLDLC 
and therefore underestimates LDLC at high TG concentra-
tions [44]. The equation is increasingly inaccurate at TG 
concentrations from 2.3 to 4.5  mmol/L [44]. The error is 
regarded as unacceptably large when TG are ≥4.5 mmol/L 
by NCEP and EAS guidelines or already at ≥4.0  mmol/L 
by national consensus in certain countries, and fasting 
blood samples should be used in this condition [2]. 
At  TG < 4.5  mmol/L nonfasting and fasting lipid profiles 
can be used alike for Friedewald cLDLC, when LDLC is not 
very low.
At very low LDLC concentration ranges <1.8 mmol/L, 
in which VLDLC constitutes a relatively larger fraction of 
the blood cholesterol, VLDLC overestimation at high TG 
concentration >2.3 mmol/L introduces a more significant 
error in the calculation of cLDLC [45]. The resulting under-
estimation of LDLC may translate to downward misclassi-
fication when using guideline-recommended 1.8 mmol/L 
or 1.4 mmol/L thresholds for patients at high and very high 
cardiovascular risk, respectively [4]. This may erroneously 
exclude >20% of patients for initiation or intensification 
of lipid-lowering therapy [45].
A modified equation, Martin-Hopkins cLDLC = TC – 
HDLC – TG/adjustable factor, which adjusts the TG/VLDLC 
ratio dynamically for concentrations of TG and non-HDLC 
has been developed [46]. Rather than dividing TG by a 
fixed factor of 5, the Martin-Hopkins equation requires 
the use of a 180-cell table to match each patient’s TG and 
non-HDLC with one of 180 different factors ranging from 
3.1 to 9.5, to give a more personalized estimation of VLDLC 
in mg/dL [46]. These personalized TG/VLDLC ratios were 
determined by direct comparison of TG to VLDLC concen-
trations directly measured after lipoprotein separation by 
ultracentrifugation in >106 US individuals from the Very 
Large Database of Lipids Study [46]. In this database, TG 
and non-HDLC are the two variables that explained most 
of the variance in TG/VLDLC [46].
The novel Martin-Hopkins formula improves the accu-
racy of cLDLC at various conditions including very low 
LDLC < 1.8 mmol/L and in nonfasting samples [47, 48]. We 
recommend to use it preferably in the range of TG concen-
trations 2.0−4.5 mmol/L wherein the Friedewald equation 
is less accurate [47]. However, it is not trivial to install the 
complex 180-cell approach of this formula into automated 
laboratory information systems. A smartphone applica-
tion (“LDL Cholesterol Calculator”) has been developed to 
provide immediate and automated calculation of Martin-
Hopkins cLDLC by simple input of a patient’s TC, HDLC, 
and TG data from the standard lipid profile [49].
dLDLC assays should always be used when TG con-
centration is ≥4.5  mmol/L, which is the limit of use of 
Friedewald and Martin-Hopkins equations [50], although 
above this concentration the direct assays may also show 
discordances with the CDC Reference Method and will 
not necessarily result in accurate LDLC measurement 
in every patient. Even in normotriglyceridemic samples 
and in samples with moderately elevated TG concen-
trations 2.0–4.5  mmol/L, dLDLC may not always agree 
with Friedewald cLDLC and translate to discrepant risk 
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classifications as observed in fasting as well as nonfast-
ing individuals [51]. It should be noted that most clinical 
trials demonstrating the evidence base for clinical benefit 
of LDLC lowering have used Friedewald cLDLC; thus it 
cannot be excluded that dLDLC rather than cLDLC is the 
method that misclassifies risk [1]. However, the fact that 
cLDLC calculated by either Friedewald or Martin-Hopkins 
equation depends upon three laboratory assays, that is, 
TG, TC, and dHDLC, means that three measurement errors 
are involved which inevitably introduce calculation vari-
ability (Table 5).
Effect of Lp(a)-cholesterol on LDLC
The cLDLC equations and also most dLDLC assays include 
the cholesterol content of Lp(a) [52]. Considering that an 
Lp(a) particle is composed of about 30−45% of cholesterol 
by weight, a significant overestimation of LDLC concen-
tration occurs in subjects with high and very high Lp(a) 
concentrations [52]; for example, Lp(a)-corrected LDLC is 
only ~55−70 mg/dL in a person with an LDLC concentra-
tion of 100 mg/dL and an Lp(a) concentration of 100 mg/
dL.
Lp(a)-corrected LDLC should be calculated at least 
once in patients with suspected high Lp(a), particularly in 
African Americans, in patients with nephrotic syndrome, 
in those undergoing peritoneal dialysis, and in any patient 
who does not respond sufficiently to statin therapy [1]. 
If a high Lp(a) concentration is indeed the cause for an 
apparent non-response or low response of LDLC, then it 
might not be useful to increase the dosage of statin under 
such conditions [1]. The correction is as follows with Lp(a) 
values reported in mg/dL:
Lp(a)-corrected LDLC (mg/dL)  
= LDLC (mg/dL) – [Lp(a) (mg/dL) × 0.30]
Lp(a)-corrected LDLC (mmol/L)  
= LDLC (mmol/L) – [Lp(a) (mg/dL) × 0.0078]
At this point of time, we do not provide alternative for-
mulas for Lp(a) reported in nmol/L (despite a proposed 
rough estimate of 2–2.5 ×  conversion factor from mg/dL to 
nmol/L) [25]. It has to be recognized that a simple conver-
sion of Lp(a) from mg/dL to nmol/L or vice versa has its 
limitations as probably most of the available immunoas-
says cannot measure Lp(a) in strict molar terms due to the 
size heterogeneity of apo(a) isoforms and the high prob-
ability that antibodies against apo(a) recognize a repeti-
tive KIV-2 epitope of apo(a) [53].
Recommendation – IV
 – The Martin-Hopkins modified equation may be pref-
erable for calculation of cLDLC, most importantly in 
patients with low LDLC concentration <1.8  mmol/L 
and/or TG concentrations 2.0–4.5  mmol/L, and in 
nonfasting samples [6].
 – dLDLC assays should be used for calculation of Rem-
nantC and for assessment of LDLC when TG concen-
tration is ≥4.5  mmol/L (or ≥4.0  mmol/L by national 
consensus in certain countries). However, the direct 
assays will not necessarily result in more accurate 
LDLC assessment in every patient.
 – Lp(a)-cholesterol correction of measured or calculated 
LDLC should be applied in patients with known or 
suspected high Lp(a) concentration, or if the patient 
shows a poor response to LDL-lowering therapy.
Table 5: Example of between-laboratory uncertainty when lipids are measured by different methods in a hypertriglyceridemic patient.
Test   Assumed total error   Defined concentration 
in model patient
mg/dL (mmol/L)
  Range of 
uncertainty
mg/dL (mmol/L)
TC   9%a   200 (5.2)  182–218 (4.7–5.7)
TG   15%a   250 (2.8)  212–288 (2.4–3.3)
dHDLC   −20% to +36%b   40 (1.0)  32–54 (0.8–1.4)
Non-HDLC   (derived from TC and dHDLC)   160 (4.1)  128–186 (3.3–4.8)
cLDLC (Friedewald)   (derived from TC, dHDLC, and TG)   110 (2.8)  70–144 (1.8–3.7)
cLDLC (Martin-Hopkins)   (derived from TC, dHDLC, TG, and non-HDLC)  122 (3.2)  91–151 (2.4–3.9)
dLDLC   −26% to +32%b   122 (3.2)  90–161 (2.3–4.2)
aBased on National Cholesterol Education Program (NCEP) analytical performance criteria [41]. bTotal error ranges observed by Miller et al. 
[42] across different dLDLC and dHDLC methods in dyslipidemic samples. The total error combines systematic bias and random imprecision. 
The table is not relevant for the monitoring of a patient by the same laboratory/method over time. In this situation the bias remains constant 
and only the (inevitable) imprecision is relevant. Bias should ideally be ≤4% for LDLC and ≤5% for HDLC to allow the methods to meet the 
NCEP total error goals, ≤12% and ≤13%, respectively.
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V.  LDLC test errors: are they 
clinically relevant?
The ranges of uncertainty across different LDLC methods 
are not negligible (Table 5). Between-laboratory varia-
tion of a certain patient’s measured or calculated LDLC 
can range widely over the guideline-driven critical values 
that determine the decision of therapeutic intervention 
(Table 6). Depending on the method used, different treat-
ment decisions may be taken, or confusion may arise if 
the patient’s samples for monitoring are sent to different 
laboratories using different methods or when a labora-
tory changes the method. Not uncommonly, changes in a 
patient’s LDLC test result over time are within the range of 
uncertainty of laboratory method variation and may not 
be due to therapeutic intervention [1].
These issues are, however, less relevant for the moni-
toring of the patient by the same laboratory and method 
over time. In this situation, the non-specificity bias 
remains constant over time and only the assay impreci-
sion (random error) and lot-to-lot variation are relevant, 
which may not be important given that clinicians are 
not aiming to achieve the LDLC targets exactly but often 
concentrations below it. In the present era, the percent-
age of LDLC reduction is more important than achieving 
specific targets, and indeed recent guidelines suggest that 
achievement of a >50% reduction in high- and very-high-
risk patients is paramount irrespective of baseline LDLC 
concentration [4].
The risk that errors in LDLC measurement or calcula-
tion affect the clinical decision is further attenuated by 
the recommendation that decision to initiate a treatment, 
or adjusting or shifting to another treatment, should 
not be taken on one LDLC test, but rather after multiple 
repeated testing (at  least 2 times) to allow averaging for 
intra-individual (biological) variation [41]. The EFLM Bio-
logical Variation Working Group recently revised biologi-
cal variation data [54, 55].
Recommendation – V
 – Follow-up of on-treatment lipid profiles in a patient 
should ideally be undertaken with the same method 
(and preferably in the same laboratory) to minimize 
misinterpretation of treatment effect.
 – Clinicians should be notified by the laboratory when 
the test changes from one method to another, e.g. 
through newsletters. This will enhance clinicians’ 
awareness of changes in methods as a potential cause 
of implausible test results.
 – Assay methods and their limitations should always be 
described in any publication of clinical trials or epide-
miological studies. In meta-analyses of associations 
of lipid tests with outcomes, it is critical to verify the 
comparability of quantitative data of the assays used 
in each trial.
 – A patient’s LDLC value close to therapeutic decision 
thresholds should ideally be confirmed by repeated 
measurement(s) (≥2) by the same method and then 
averaged. Often the repeated test value is lower due 
to improved diet after the first test if the patient is told 
that LDLC is elevated; in this case the second value 
should be accepted for decision-making.
Table 6: Primary and secondary goals of preventive therapy according to cardiovascular mortality risk categories assessed with the SCORE 
system [4].
Risk (SCORE)a  LDLC mmol/L (mg/dL)   Non-HDLCb mmol/L (mg/dL)  ApoBb g/L (mg/dL)
Very high   <1.4 (55) and ≥50% reduction in LDLC   <2.2 (85)c  <0.65 (65)d
High   <1.8 (70) and ≥50% reduction in LDLC   <2.6 (100)  <0.80 (80)
Moderate   <2.6 (100)   <3.3 (130)  <1.00 (100)
Low   <3.0 (115)    
a10-year risk of fatal ASCVD as estimated using SCORE (Systematic COronary Risk Evaluation) [4]. Very high risk  =  documented ASCVD, 
diabetes with target organ damage (proteinuria, retinopathy, or neuropathy), or early onset type 1 diabetes of >20 years’ duration, 
severe chronic kidney disease (GFR < 30 mL/min/1.73 m2), SCORE ≥ 10%; High risk  =  TC > 8 mmol/L (310 mg/dL), LDLC > 5 mmol/L 
(190 mg/dL), FH, hypertension ≥ 180/110 mmHg, diabetes of ≥10 years’ duration without target organ damage, moderate chronic kidney 
disease (GFR 30–59 mL/min/1.73 m2), SCORE ≥ 5% and <10%; Moderate risk  =  young patients with diabetes (type 1 < 35 years, type 2 
< 50 years) of <10 years’ duration, SCORE ≥ 1% and <5%; Low risk  =  SCORE < 1%. bSecondary target in patients with mild-to-moderate 
hypertriglyceridemia, 2–10 mmol/L (175–880 mg/dL) including those with obesity or metabolic syndrome, diabetes, or chronic kidney 
disease. cDiscordant high non-HDLC at optimal LDLC goal reflects elevated RemnantC >0.8 mmol/L (30 mg/dL). dDiscordant high apoB at 
optimal LDLC goal reflects elevated numbers of small, cholesterol-depleted LDL particles. To convert mmol/L to mg/dL, multiply by 38.6 for 
LDL and non-HDL cholesterol.
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Calculated by subtracting HDLC from TC, non-HDLC rep-
resents the cholesterol in all particles causing cardiovas-
cular disease, that is, LDL, VLDL, IDL, and Lp(a); in the 
nonfasting state this additionally includes the cholesterol 
in chylomicrons and their remnant particles [1]. Non-
HDLC provides a more comprehensive risk assessment 
than LDLC in certain individuals with hypertriglyceri-
demia because it adds RemnantC to LDLC and, therefore, 
takes into account the atherogenic potential of remnant 
lipoproteins [17]. However, non-HDLC cannot substitute 
for RemnantC because it does not differentiate between 
RemnantC and LDLC and Lp(a)-cholesterol. Some indi-
viduals with high RemnantC have low LDLC and thus will 
have relatively low non-HDLC if Lp(a) is also low, and if 
interpreting non-HDLC instead of RemnantC, the high 
RemnantC will be masked in these individuals [30].
Like LDLC, non-HDLC is treatable with existing lipid-
lowering agents and there is a direct, consistent relation-
ship between the magnitude of non-HDLC lowering and 
cardiovascular risk reduction observed in meta-analyses 
and trials with statins and other lipid-lowering agents 
[56, 57]. Guideline-recommended therapeutic goals for 
 non-HDLC are arbitrarily set typically at 0.8  mmol/L 
(30 mg/dL) higher than LDLC goals (Table 6); this value 
is based on the assumption that the “optimal” VLDLC 
concentration associated with the fasting TG threshold 
1.7 mmol/L is 0.8 mmol/L, as estimated by the Friedewald 
formula (TG/2.2) [1, 2].
Non-HDLC can be obtained in the nonfasting state and 
does not require TG to be less than 4.5 mmol/L, which is the 
limitation for calculation of cLDLC [44]. However, dHDLC 
measurement errors in hypertriglyceridemic samples still 
affect the calculation of non-HDLC and most assays limit 
the measurement of dHDLC to TG < 10  mmol/L. Despite 
this limitation, non-HDLC yields more accurate cardio-
vascular risk classification than either Friedewald cLDLC 
or dLDLC, and also more consistent risk scores using dif-
ferent manufacturers’ assays for dHDLC in the calculation 
[58]. Non-HDLC shows better correlation and concord-
ance with cLDLC when using the Martin-Hopkins formula 
compared to the Friedewald equation in patients with 
atherogenic dyslipidemia [59]. When compared to Mar-
tin-Hopkins cLDLC, non-HDLC translates to only modest 
improvement for risk classification that could change 
clinical management (in ~2% of individuals in the general 
population), although discordance of Martin-Hopkins 
cLDLC and, as a consequence, risk underestimation is still 
common (80–90%) in patients with TG ≥ 4.5 mmol/L [60].
Apolipoprotein B
In contrast to the heterogeneous LDLC fraction, apoB is 
a clearly defined measurand. It is the structural protein 
for all non-HDL lipoproteins and exists as two isoforms: 
apoB100, the major isoform in VLDL, IDL, LDL, and 
Lp(a), and apoB48 in chylomicrons and chylomicron rem-
nants [12]. ApoB100 contains the ligand that binds to the 
LDL receptor. As each atherogenic particle contains one 
molecule of apoB, concentrations of apoB are therefore 
considered to be a direct measure of the total number of 
lipoproteins causing cardiovascular disease, that is, LDL, 
remnants, and Lp(a) [12].
ApoB quantification by automated immunoassays 
such as immunonephelometry and immunoturbidimetry 
can be easily implemented in the clinical laboratories. 
These immunoassays obviate the need for lipoprotein 
subfractionation techniques such as nuclear magnetic 
resonance (NMR) spectroscopy or ion mobility to quantify 
LDLP and have been shown to be at least equivalent to 
LDLP in predicting cardiovascular risk [61, 62]. However, 
apoB cannot substitute for NMR- or ion mobility-based 
particle size measurements and does not differentiate 
between LDLP and VLDL particle numbers [61, 62]. A 
major impediment to LDLP testing is its limited availabil-
ity in the clinical laboratories, higher cost, and lack of 
standardization [63], although it does provide additional 
information on other lipoproteins VLDL and HDL, beyond 
LDLP.
ApoB can be measured in the nonfasting state because 
even at peak postprandial concentrations, the number of 
chylomicron-apoB48 particles in healthy individuals is 
usually <1% and the number of VLDL-apoB100 particles is 
<10% of the number of LDL-apoB100 particles [12]. Thus, 
even when cross-reactivity of immunoassays to apoB48 
occurs in nonfasting measurements, apoB quantification 
is essentially an estimate of LDLP number if TG and Lp(a) 
concentrations are low [1]. Far higher than the maximum 
allowed TG concentration of 4.5 mmol/L for cLDLC, most 
nephelometric and turbidimetric apoB measurements are 
limited to TG <10 mmol/L due to interference of light scat-
tering or absorption caused by chylomicrons and large 
VLDLs; a TG concentration above this limit in nonfasting 
blood samples is only seen in ~0.1% of individuals in the 
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general population [17]. Nevertheless, it is cautious to con-
sider fasting apoB measurement when TG concentration 
in the nonfasting sample is ≥4.5 mmol/L [2].
The International Federation of Clinical Chemistry 
(IFCC) and World Health Organization (WHO) developed 
the SP3 reference material, value-assigned using immu-
nonephelometry as interim reference method for apoB 
[64]. Common calibration with the IFCC/WHO SP3 refer-
ence material has reduced between-laboratory variabil-
ity of apoB measurements from >19% to <10%, although 
concerns about the variability among immunoassays and 
their comparability with apoB100 derived from NMR and 
other methods still exist [65–67]. Liquid chromatography 
tandem-mass spectrometry (LC-MSMS)-based quanti-
fication of apolipoproteins has the potential to further 
improve apoB100  standardization and between-method 
comparability [67]. The IFCC has therefore initiated devel-
opment of LC-MSMS as candidate definitive reference 
method for apoB [67]. Another advantage of LC-MSMS is 
that it enables the simultaneous (multiplexed) measure-
ment of multiple apolipoproteins in addition to apoB100 
in a single run of the assay, thus making it possible to 
achieve a complete apolipoprotein profile in the patient, 
including HDL- and VLDL-associated apolipoproteins for 
comprehensive characterization of dyslipidemias [68]. 
Although nowadays throughput of LC-MSMS is low com-
pared to immunoassays, automated LC-MSMS systems are 
developed and will become available for implementation 
in high-throughput clinical laboratories.
Given the improvements of standardization initi-
ated by the IFCC [69], measurements of apolipoproteins 
have the potential to meet analytical performance criteria 
including accuracy, harmonization across laboratories, 
unambiguous definition of the measurand, and unequiv-
ocal test results in both normo- and dyslipidemic sera 
– important prerequisites for medical use of a test which 
cannot be met with LDLC and non-HDLC measurements 
or calculations.
Recommendation – VI
 – ApoB measurement is superior to LDLC and non-
HDLC measurements and calculations for the assess-
ment of exposure to atherogenic lipoprotein particle 
numbers in the circulation.
 – ApoB is recommended for risk assessment and may 
be preferred over non-HDLC, if available, in per-
sons with mild-to-moderate hypertriglyceridemia 
(2–10  mmol/L), diabetes, obesity or metabolic syn-
drome, or very low LDLC < 1.8 mmol/L [4].
 – Like non-HDLC, apoB can always be measured in the 
nonfasting state and is not affected by biological TG 
variability.
VII.  Can apoB measurement replace 
the standard lipid profile for 
monitoring of lipid-lowering 
therapies?
Although the traditional lipid profile of TC, TG, HDLC, and 
LDLC remains essential for dyslipidemia diagnosis and 
ASCVD risk categorization, the position of LDLC as treat-
ment target is challenged by the analytical performance of 
apoB. However, the apoB test has not yet been completely 
validated for this clinical purpose according to key criteria 
defined by the EFLM Test Evaluation Working Group [70] 
– clinical performance, clinical effectiveness, and cost-
effectiveness – beyond analytical performance to become 
a medically useful test (Table 7).
Clinical performance – risk estimation
Data and meta-analyses of prospective population-based 
cohort studies [71–74] and statin trials [75, 76] suggest that 
the clinical performance of apoB and non-HDLC, although 
superior to LDLC in some studies, is on average compa-
rable to dLDLC, Friedewald cLDLC, or Martin-Hopkins 
cLDLC to predict risk of fatal or nonfatal ASCVD on the 
population level. Risk associations are similar in nonfast-
ing study populations than in those who did fast [72, 74].
For a majority of patients in whom apoB tests corre-
late with LDLC, measurement of traditional lipids should 
suffice to estimate risk. However, in ~20% of individuals 
in whom apoB is discordantly high with respect to popu-
lation percentiles of LDLC, cardiovascular risk tracks with 
apoB, suggesting that replacing LDLC by apoB would 
identify more individuals with increased risk of ASCVD 
[74] – this implies an overall better clinical performance 
compared to LDLC in particular among this smaller subset 
of individuals with discordant apoB.
Clinical effectiveness – risk reduction
The substantial residual risk that persists in LDLC-tar-
geted therapies even at LDLC < 1.8  mmol/L has fueled 
the debate about considering using apoB rather than 
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LDLC as treatment target. Meta-analyses of lipid-lower-
ing trials showed that statins and other therapies which 
clear apoB-containing lipoproteins by upregulating LDL 
receptor expression, such as PCSK9 inhibitors, reduce car-
diovascular risk proportional to the decrease in apoB con-
centration observed in these trials [77, 78]. Furthermore, 
Mendelian randomization studies demonstrated that the 
reduction in cardiovascular risk associated with genetic 
variation in clearance and processing of apoB-containing 
lipoproteins, including LDLPs as well as TG-rich VLDL par-
ticles and their remnants, was correlated with the change 
of concentration of these particles as measured by apoB 
rather than the cholesterol mass carried by those particles 
as measured by LDLC [79, 80]. These findings suggest a 
potential role of apoB as therapeutic target.
Cost-effectiveness – health-economic benefit
Implementation of apoB assays in follow-up of lipid-
lowering therapies would impose healthcare systems 
and patients with yearly extra cost, although one might 
consider replacing the standard lipid profile (needed 
for calculation of LDLC and non-HDLC) by single fol-
low-up measurement of apoB in order to attenuate the 
rise of expenses. The suggested use of apoB would be 
cost- effective if these tests guide therapy to reduce the 
healthcare costs of ASCVD to a greater extent than stand-
ard therapy guided by LDLC, yet the evidence base of this 
approach is still incomplete (Table 7). To evaluate the 
cost-effectiveness of apoB-guided treatment, randomized 
trials should be designed in which patients are rand-
omized to receive the apoB test vs. the standard LDLC test 
and the health economic outcome(s) of identifying and 
treating more patients at high risk (i.e. not identified or 
treated when using the standard test) is assessed [1].
Recommendation – VII
 – At this point of time, there is insufficient evidence of 
benefit from outcome studies to support the option to 
replace the standard lipid profile (with calculation of 
cLDLC and non-HDLC) by single follow-up measure-
ment of apoB to guide lipid-lowering therapies.
 – The clinical effectiveness of LDLC-guided manage-
ment of cardiovascular risk is most strongly evidence-
based [7, 8]. All guidelines concur that LDLC remains 
the primary target of lipid-lowering strategies to pre-
vent ASCVD [4–6]. Lowering LDLC to concentrations 
below a target of 1.8 mmol/L in patients at high car-
diovascular risk or 1.4 mmol/L in patients at very high 
risk (or by ≥50% if these targets cannot be attained) is 
of critical importance [4].
Table 7: Contemporary evidence for the medical use of LDLC, non-HDLC, apoB, and LDLP based on essential test characteristics [1].
Test characteristics LDLC non-HDLC ApoB LDLP
Analytical performancea
 Precise assays Yes Yes Yes Yes
 Accurate assays (method independency) No No Yes No
 Nonfasting measurement possible cLDLC at TG < 4.5 mmol/L Yes Yes Yes
 Widely accessible assays Yes Yes Yes No
 Reasonable operational costs Yes No extra measurement Yes Not yet
Clinical performanceb
 Robust associations with incident ASCVD? Yes Yes Yes Yes
 Novel information beyond existing markers? (Reference) Yes Yes Yes
 Validated decision thresholds? No No No No
Clinical effectivenessc
 Superiority to existing tests? (Reference) Probably Probably Probably
 Modifiable risk association (treatment target)? Yes Yes Yes Yes
 Test-guided treatment reduces ASCVD risk? Yes Probably Probably Unknown
Cost-effectivenessd
 Test-guided treatment saves healthcare costs? Yes Unknown Unknown Unknown
Test characteristics defined by the EFLM Test Evaluation Working Group [70]: (a) Analytical validity: ability of the test to conform to 
predefined quality specifications to measure the marker of interest. (b) Diagnostic or prognostic accuracy: ability of the test to consistently 
discriminate patients with increased risk from those with lower risk for developing ASCVD. (c) Clinical utility: ability of the test to improve 
health outcomes of the patient under standard clinical care. (d) Health-economic advantage of introducing the test in medical practice 
(value for money).
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VIII.  Should non-HDLC or apoB 
be used as additional tests 
to LDLC in lipid-lowering 
strategies?
Non-HDL cholesterol
Data from concordance/discordance analyses suggest that 
calculation of non-HDLC is at least equally good at predict-
ing ASCVD compared with measurement or calculation of 
LDLC in the overall population and statin-treated patients; 
it may also be superior to LDLC if discordantly high, espe-
cially at normal or low LDLC concentrations and in individu-
als with hypertriglyceridemia because it includes RemnantC 
[81–83]. LDLC does not provide incremental risk prediction 
of ASCVD relative to non-HDLC [81–83]. The only concern is 
the threshold concentration selected in some studies: it may 
be the more sensitive threshold for non-HDLC as compared 
to LDLC rather than the biomarker which makes the differ-
ence. Guideline-based non-HDLC thresholds have been arbi-
trarily defined by consensus of expert groups, based on the 
assumption that a normal VLDLC concentration exists when 
TG are <1.7 mmol/L, which is <0.8 mmol/L as estimated by 
the Friedewald formula [1, 2]. Lowering non-HDLC thresh-
olds leads to upward reclassification of patients (if the goal 
is to reduce undertreatment), and higher thresholds lead to 
downward reclassification (if the goal is to reduce overtreat-
ment). Threshold values need to be validated in clinical per-
formance studies, to evaluate which values most accurately 
classify patients within risk categories [70].
For the present purposes, the combination of non-HDLC 
with Martin-Hopkins cLDLC may be considered as an appro-
priate strategy to guide therapy and they can be calculated 
from the standard lipid profile [1]. This may compensate 
for the under- or overestimation of LDLC in terms of clini-
cal decision-making, given the uncertainty of dLDLC meas-
urements or the Friedewald calculation in dyslipidemic 
samples when LDLC lowering approaches 1.4 mmol/L, and 
non-HDLC can be used at high TG ≥ 4.5 mmol/L. However, 
the compromised accuracy of dHDLC assays in samples 
with hypertriglyceridemia reduces the benefit in reporting 
non-HDLC in some individuals in whom an apoB or LDLP 
measurement may be clinically useful [1].
Apolipoprotein B
Data from concordance/discordance analyses in large 
case-control and prospective cohort studies reveal that the 
addition of apoB to LDLC and even to non-HDLC has the 
potential to improve risk prediction by identifying more 
high-risk individuals [74, 84–86]. This is consistent with 
the notion that risk of ASCVD is more directly related to the 
number of apoB-containing particles (reflected by apoB 
measurement) than to the cholesterol content of lipopro-
teins [10]. The implication of discordant LDLC vs. apoB 
(one normal, the other high) is most evident in patients 
with predominant small, cholesterol-depleted LDLPs who 
present with “optimal” concentrations of TC and LDLC – a 
profile that is especially prevalent among individuals with 
the metabolic syndrome or diabetes and in those taking 
medications, such as statins and anti-PCSK9, that reduce 
LDLC to a greater extent than apoB [87–89]. This necessarily 
results in on-treatment LDLP and VLDL particle numbers 
that are higher than would be anticipated from the concur-
rent LDLC follow-up measurement and may explain part of 
residual risk among statin-treated patients [62, 90].
In patients with a moderate estimated risk score, in 
particular those with additional metabolic risk factors, 
apoB (or LDLP) measurement as a “risk-enhancing factor” 
could be useful [6]. Presence of risk-enhancing factors 
including apoB can tip the balance toward earlier initia-
tion of drug treatment in shared decision-making between 
clinician and patient, especially in primary prevention if 
goals cannot be achieved with lifestyle advice [6].
Secondary treatment target: non-HDLC 
or apoB?
Guidelines propose using non-HDLC or apoB as a secondary 
treatment target in the management of patients with mild-
to-moderate hypertriglyceridemia (2–10 mmol/L), including 
patients with diabetes [4, 5]. If the primary target LDLC is at 
goal, but non-HDLC or apoB is still high, attainment of all 
three targets will require intensified lipid-lowering therapy, 
lifestyle (re)inforcement, and/or additional TG-lowering 
drugs (e.g. fibrate or omega-3 fatty acids) [4]. Addition of 
PCSK9 inhibition to statin therapy allows more patients to 
achieve non-HDLC and apoB goals and lower risk of ASCVD, 
with no attenuation of benefit at lower concentrations [88].
Which to choose as a secondary target: non-HDLC 
or apoB? Although apoB demonstrates competitive clini-
cal performance compared with non-HDLC, there is no 
evidence yet of significant population health-economic 
benefit of intensifying pharmacological intervention 
aiming to further reduce apoB at very low concentrations 
of LDLC [1]. For now and until this issue is clarified, non-
HDLC is an acceptable choice and it can be used without 
the additional expense of extra measurement.
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Recommendation – VIII
 – Use of non-HDLC or apoB should be considered as an 
index of the efficacy of treatment targeted at LDLC. For 
the present purpose, every lipid profile report should 
automatically add non-HDLC. To improve patient com-
fort and compliance, there are practical advantages of 
this approach for follow-up without the need to fast [2].
 – At TG concentration ≥4.5  mmol/L, a condition 
wherein use of Friedewald cLDLC or Martin-Hopkins 
cLDLC is not recommended and also dLDLC is likely 
to be inaccurate, use of non-HDLC calculation may be 
considered instead of dLDLC measurement to evalu-
ate therapeutic response.
IX.  How to report the atherogenic 
lipid profiles?
Threshold values
We recommend that laboratory reports should flag abnor-
mal concentrations based on threshold values defined by 
guidelines, i.e. decision threshold to trigger therapy or to 
identify increased risk of ASCVD (Table 8). For nonfasting 
samples, laboratories should flag abnormal TG concen-
trations as ≥2  mmol/L according to the Women’s Health 
Study, which found that this threshold was optimal for 
ASCVD prediction [91]. The threshold for fasting TG at 
1.7  mmol/L is 0.3  mmol/L lower than for nonfasting TG, 
corresponding to the mean maximal increase in TG fol-
lowing habitual food intake [2]. Nonfasting state-adjusted 
thresholds for RemnantC and, consequently, also non-
HDLC may be considered as an option (Table 8). In case 
the patient’s postprandial time in the preceding 12  h is 
unknown on sample reception in the laboratory, it may 
remain prudent to apply the lower fasting thresholds to 
draw attention to a potential cardiovascular risk.
For LDLC, the decision threshold for initiation of 
therapeutic intervention varies with the individual’s risk 
score (Table 6) [4]. This personalized reporting of optimal 
thresholds is difficult to implement in laboratory reports 
because usually the clinical conditions and risk factors 
of the individual patients are not known to the labora-
tory personnel. We therefore propose a simplified flagging 
based on the threshold for low risk only (3 mmol/L), which 
may be complemented by more detailed information on 
Table 8: Flagging of abnormal lipid and (apo)lipoprotein concentrations based on risk prediction thresholds and of extremely abnormal 
concentrations [2].
Parameter   Thresholds   Interpretative commenting
TGa   Fasting ≥ 1.7 mmol/L (150 mg/dL)
Nonfasting ≥ 2 mmol/L (175 mg/dL)
  >10 mmol/L (880 mg/dL): severe hypertriglyceridemia with high risk of acute 
pancreatitis
TC   ≥5 mmol/L (190 mg/dL)  
LDLC   ≥3 mmol/L (115 mg/dL)   >13 mmol/L (500 mg/dL): consider homozygous FH
>5 mmol/L (190 mg/dL): consider heterozygous FH
RemnantC   Fasting ≥ 0.8 mmol/L (30 mg/dL)
Nonfasting ≥ 0.9 mmol/L (35 mg/dL)
 
Non-HDLC   Fasting ≥ 3.8 mmol/L (145 mg/dL)
Nonfasting ≥ 3.9 mmol/L (150 mg/dL)
 
ApoB   ≥1 g/L (100 mg/dL)   <0.1 g/L (10 mg/dL): genetic abetalipoproteinemia
HDLC   Men ≤ 1 mmol/L (40 mg/dL)
Women ≤ 1.2 mmol/L (45 mg/dL)
 
ApoA-I   Men ≤ 1.2 g/L (120 mg/dL)
Women ≤ 1.4 g/l (140 mg/dL)
  <0.1 g/L (10 mg/dL): genetic hypoalphalipoproteinemia
Lp(a)   ≥50 mg/dL (>105 nmol/L)b,c   >120 mg/dL: very high risk for myocardial infarction and aortic valve stenosis
Values in mmol/L were converted to mg/dL by multiplication by 38.6 for cholesterol and 88.5 for TG, followed by rounding to the nearest 
5 mg/dL. aTG thresholds based on assays with correction for endogenous glycerol. The free glycerol concentration in a sample, usually  
1 mg/dL, equivalent to ~10 mg/dL (0.11 mmol/L) of TG, can be ignored. Increased baseline glycerol concentrations can be found in patients 
with diabetes and chronic kidney disease and during intravenous lipid infusion, and TG may be wrongly flagged in these patients unless 
glycerol-corrected TG assay is used. bThreshold value for Lp(a) should represent ≥80th percentile of the population-specific Lp(a) assay. 
cThere is no consensus on which threshold value in mmol/L to be used for Lp(a); however, for conversion of Lp(a) concentrations in mg/dL to 
nmol/L, 13,930 individuals from the Copenhagen General Population Study had measurements in both mg/dL and nmol/L by Denka Seiken 
assays distributed by Roche Diagnostics (Rotkreuz, Switzerland). The correlation was done by linear regression with an R2 value of 0.996, 
and the conversion was done by the following equation: Lp(a), nmol/L = 2.18*Lp(a), mg/dL–3.83 [3].
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risk-stratified thresholds in footnotes on the laboratory 
report or by references to web-based information [2].
Given the uncertainty of measurements and calcula-
tions of LDLC across different methods and laboratories, 
in hypertriglyceridemic patients the decision thresholds 
may not always be assumed to be universally applicable 
[1]. Guideline-recommended LDLC thresholds are based 
on observations with Friedewald cLDLC using the older 
HDLC precipitation methods which differ from dHDLC 
assays used nowadays. This situation is challenging for 
new generation assays to meet regulations for in  vitro 
diagnostic medical devices, requiring evidence of clinical 
performance of the assays [70].
Reference limits
Usually, in laboratory reports, results of most tests are 
flagged if they are below or above the age- and sex-specific 
reference interval (2.5th–97.5th percentiles). Because of 
the widespread unhealthy lifestyle, in most populations 
the upper reference limits of TC, LDLC, and TG are very 
high and far above the thresholds of increased ASCVD risk 
(Tables 2 and 3, Figure 2). Therefore, flagging of lipid pro-
files in adults should not be based on reference limits [2]. 
In a pediatric setting, reporting age- and gender-specific 
reference intervals is relevant for early identification of 
children with hyperlipidemia associated with premature 
atherosclerosis, especially FH [32].
Reference nonfasting concentrations in adults from 
the Copenhagen General Population Study are reported in 
Tables 2 and 3. Reference intervals in children and adoles-
cents are available from recent population-based cohort 
studies and databases [92–94]. Countries are encouraged 
to establish reference intervals in their local populations, 
to account for differences in lifestyle and risk factors in dif-
ferent European regions. Ideally, these reference intervals 
should be regularly updated because significant changes 
in population lipid concentrations occur mainly related to 
the substantial increase in unhealthy lifestyle and obesity 
and changes of analytical methods over time [95–97]. In the 
adoption of published reference concentrations with known 
biological or analytical sources of variation, the clinical 
laboratory should verify the reference interval with its own 
analytical method on 20 samples drawn from its local popu-
lation under similar pre-analytical conditions [96, 97]. If ≤2 
of 20 values (≤10%) fall outside the reference interval, then 
the interval can be adopted [96, 97]. For decision thresholds 
it is unnecessary to validate them in the laboratory [97].
Alert values
Using decision thresholds for flagging will lead to many 
lipid profiles reported with flags, as with more than 50% 
Figure 2: Distribution of nonfasting LDLC concentration in men and women from the Copenhagen General Population Study not on lipid-
lowering therapy.
Nonfasting TG, TC, and HDLC were measured by automated assays (Thermo Scientific Konelab, Vantaa, Finland). LDLC was calculated by the 
Friedewald equation when TG were <4 mmol/L and was measured directly (Konelab) when TG were ≥4 mmol/L [3]. Population percentages 
of men and women are subdivided according to LDLC values above 5 mmol/L (roughly the 95th percentile above which FH should be 
considered), between 3 and 5 mmol/L, and below 3 mmol/L (the guideline-recommended threshold). Flagging based on reference intervals 
instead of threshold values should be avoided, as use of reference limits would not flag a majority of LDLC test results (~60%) associated 
with increased ASCVD risk. Age-stratified LDLC data can be seen in Tables 2 and 3.
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of LDLC results (Figure 2). There is a risk that flagging too 
many results will make the physician ignore very high 
concentrations and may distract from the severe dyslipi-
demias, especially when used for screening in primary 
care. We have considered this by defining alarming values 
for extreme dyslipidemias, where we recommend special 
notification and reaction from the laboratory [2].
Extremely abnormal test results should be flagged 
with special alert notifications to quickly initiate further 
diagnostic and possibly therapeutic actions by the cli-
nician (Table 8). For example, patients with severe 
hypertriglyceridemia ≥10  mmol/L and chylomicronemia 
syndrome have high risk of acute pancreatitis but usually 
do not develop premature atherosclerosis, probably 
because chylomicrons and large VLDLs do not traverse the 
vascular endothelial barrier [33]. Lp(a) above the 97.5th 
percentile (>120 mg/dL depending on the assay) should 
be noted because of very high risk for myocardial infarc-
tion and aortic valve stenosis [2]. Any LDLC > 5 mmol/L in 
adults or >4 mmol/L in children should trigger investiga-
tions to rule out FH and, if diagnosis of FH is confirmed 
in the index case, cascade family screening [31, 32]. In 
patients with mixed hyperlipidemias, routine genetic 
testing is not warranted [33]. Reflective testing can pro-
actively assist clinicians to rule out common secondary 
causes of hyperlipidemia using additional tests, e.g. thy-
rotropin, hemoglobin A1c, liver enzymes, and creatinine/
eGFR, if not already known to the clinician at first-time 
screening [98].
Recommendation – IX
 – Flagging of lipid profiles on laboratory reports should 
always be based on decision thresholds. In children, 
reporting of reference intervals is relevant.
 – Extremely high concentrations should automati-
cally trigger alerts to initiate immediate diagnostic 
investigations.
Conclusions and future research 
priorities
The consensus-based recommendations of EAS and EFLM 
provide guidance for the use of contemporary lipid, lipo-
protein, and apolipoprotein tests to assist clinicians in 
their strategies to prevent ASCVD [1, 2]. These recommen-
dations take into account the strengths and weaknesses 
of the tests in terms of key criteria to become a medically 
useful test, as defined by the EFLM Test Evaluation 
Working Group [70].
Calculation of non-HDLC and RemnantC from the 
standard lipid profile, ‘expanded’ testing of apoB and 
Lp(a), and ‘advanced’ testing of LDLP have the potential to 
address clinical needs unmet with LDLC testing and they 
can always be used in nonfasting samples. The research 
priority is to investigate whether the diagnostic informa-
tion provided by ‘expanded’ or ‘advanced’ lipid profiles 
can sufficiently change clinical management to reduce 
the risk (and cost) of ASCVD to a greater extent than the 
standard LDLC-centered approach.
Diabetes and abdominal obesity, disorders that 
underlie the clinical expression of complex dyslipidemias 
without elevated LDLC, are attaining epidemic propor-
tions [11]. Hence, emerging and advanced lipoprotein 
testing will likely become more and more useful in the 
future. This underscores the need to standardize and 
validate advanced lipoprotein tests, such as NMR- or ion 
mobility-based LDLP and VLDL particle numbers and 
size [62, 63], and multiplexed LC-MSMS apolipoprotein 
profiles [68], which have the potential to become widely 
available medical tests [99]. These novel technologies 
provide complementary diagnostic information regard-
ing the complex molecular basis of dyslipidemias and, as 
such, can be used to explore and evaluate precision medi-
cine approaches for identifying better and individualized 
treatment options for patients at high risk of ASCVD [99].
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